WO2025062362 - IL-5R-ALPHA ANTIBODIES FOR TREATING EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
National phase entry:
Publication Number
WO/2025/062362
Publication Date
27.03.2025
International Application No.
PCT/IB2024/059168
International Filing Date
20.09.2024
Title **
[English]
IL-5R-ALPHA ANTIBODIES FOR TREATING EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
[French]
ANTICORPS IL-5R-ALPHA POUR LE TRAITEMENT DE LA GRANULOMATOSE ÉOSINOPHILE AVEC POLYANGÉITE
Applicants **
ASTRAZENECA AB
Inventors
DUNCAN, Elizabeth
NECANDER, Sofia
D'ANGELO, Gina
BÖRJESSON SJÖ, Lena
Priority Data
63/584,453
21.09.2023
US
63/597,634
09.11.2023
US
63/648,325
16.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4206 | |
| EPO | Filing, Examination, Granting | 48597 | |
| Japan | Filing, Examination, Granting | 3727 | |
| South Korea | Filing, Examination, Granting | 5325 | |
| USA | Filing, Examination, Granting | 14390 |
Total:
76,245
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein are methods of treating Eosinophilic Granulomatosis with Polyangiitis (EGPA) comprising administering to the subject a therapeutically effective amount of an anti- interleukin-5 receptor alpha (IL-5Rα) antibody or an antigen-binding fragment thereof such as benralizumab.[French]
L'invention concerne des méthodes de traitement de la granulomatose éosinophile avec polyangéite (GEPA) comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un anticorps anti-récepteur alpha de l'interleukine-5 (IL-5Rα) ou d'un fragment de liaison à l'antigène de celui-ci tel que le benralizumab.